[go: up one dir, main page]

WO2010047561A3 - Diagnostic kit for predicting the prognosis of invasive or non-muscle invasive bladder cancer, method for predicting the prognosis of bladder cancer, and bladder cancer medicine screening method - Google Patents

Diagnostic kit for predicting the prognosis of invasive or non-muscle invasive bladder cancer, method for predicting the prognosis of bladder cancer, and bladder cancer medicine screening method Download PDF

Info

Publication number
WO2010047561A3
WO2010047561A3 PCT/KR2009/006160 KR2009006160W WO2010047561A3 WO 2010047561 A3 WO2010047561 A3 WO 2010047561A3 KR 2009006160 W KR2009006160 W KR 2009006160W WO 2010047561 A3 WO2010047561 A3 WO 2010047561A3
Authority
WO
WIPO (PCT)
Prior art keywords
bladder cancer
prognosis
predicting
invasive
diagnostic kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/006160
Other languages
French (fr)
Korean (ko)
Other versions
WO2010047561A2 (en
Inventor
김원재
배석철
김용준
김선규
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIORUNX Co Ltd
Original Assignee
BIORUNX Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIORUNX Co Ltd filed Critical BIORUNX Co Ltd
Publication of WO2010047561A2 publication Critical patent/WO2010047561A2/en
Publication of WO2010047561A3 publication Critical patent/WO2010047561A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a diagnostic kit for predicting the prognosis of invasive or non-muscle invasive bladder cancer, to a method for predicting the prognosis of bladder cancer, and to a bladder cancer medicine screening method. More particularly, the present invention relates to a diagnostic kit for predicting the prognosis of bladder cancer, comprising, as active ingredients, primer pairs, a probe, or an antibody for a gene-classifier which statistically analyzes gene expression among normal tissues and bladder cancer tissues by using a micro-array to predict the reoccurrence or progression of non-muscle invasive bladder cancer, or for a gene-classifier which may predict the progression of invasive bladder cancer, cancer-specific survival, or total survival. The present invention also relates to a method for predicting the prognosis of bladder cancer using the primer pairs, the probe, or the antibody. The method of the present invention predicts the prognosis of bladder cancer in an inexpensive, convenient, and quick manner, and is useful in screening bladder cancer medicine.
PCT/KR2009/006160 2008-10-24 2009-10-23 Diagnostic kit for predicting the prognosis of invasive or non-muscle invasive bladder cancer, method for predicting the prognosis of bladder cancer, and bladder cancer medicine screening method Ceased WO2010047561A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0104773 2008-10-24
KR1020080104773A KR20100045703A (en) 2008-10-24 2008-10-24 Diagnosis kit for prognosis-prediction of invasive or non-muscle invasive bladder cancer, method for estimating prognosis of bladder cancer and method for screening therapeutic agent of bladder cancer

Publications (2)

Publication Number Publication Date
WO2010047561A2 WO2010047561A2 (en) 2010-04-29
WO2010047561A3 true WO2010047561A3 (en) 2010-11-18

Family

ID=42119860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006160 Ceased WO2010047561A2 (en) 2008-10-24 2009-10-23 Diagnostic kit for predicting the prognosis of invasive or non-muscle invasive bladder cancer, method for predicting the prognosis of bladder cancer, and bladder cancer medicine screening method

Country Status (2)

Country Link
KR (1) KR20100045703A (en)
WO (1) WO2010047561A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101683961B1 (en) * 2014-03-31 2016-12-07 동아대학교 산학협력단 Recurrence Marker for Diagnosis of Bladder Cancer
KR101750146B1 (en) * 2014-12-30 2017-06-23 충북대학교 산학협력단 Use of RSPH9 for Prognostic Marker Diagnosis of Bladder Cancer
EP3333268A1 (en) * 2016-12-09 2018-06-13 Institut Paoli Calmettes Biomarker panel for prognosis of bladder cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EWISS ET AL.: "Gene expression profile in squamous cell carcinoma of the urinary bladder using complementary deoxyribonucleic acid microarray.", UROL. ONCOL., vol. 25, no. 2, 23 March 2007 (2007-03-23), pages 120 - 127 *
GOTTARDO ET AL.: "MicroRNA profiling in kidney and bladder cancers", UROL. ONCOL., vol. 25, no. 5, 7 September 2007 (2007-09-07), pages 387 - 392 *
KAWAKAMI ET AL.: "Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling", ONCOL. REP., vol. 16, no. 3, September 2006 (2006-09-01), pages 521 - 531 *
KIM ET AL.: "Molecular biomarkers in urothelial bladder cancer", CANCER SCI., vol. 99, no. 4, 28 March 2008 (2008-03-28), pages 646 - 652 *

Also Published As

Publication number Publication date
WO2010047561A2 (en) 2010-04-29
KR20100045703A (en) 2010-05-04

Similar Documents

Publication Publication Date Title
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2008115419A3 (en) Gene expression markers for prediction of patient response to chemotherapy
MX2009013646A (en) Methods of diagnosing and treating cancer.
EP3296406A3 (en) Mirna fingerprint in the diagnosis of lung cancer
ES2530843T3 (en) MicroRNA based methods for the diagnosis of pancreatic cancer
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2011072177A3 (en) Biomarker assay for diagnosis and classification of cardiovascular disease
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
EP2374884A3 (en) Human miRNAs isolated from mesenchymal stem cells
MX336675B (en) Screening for anti-cancer compounds using netrin-1 activity.
WO2008137693A3 (en) Retinal flow cytometry
WO2010092164A3 (en) Bacterial dna as markers of cardiovascular and/or metabolic disease
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2011047058A3 (en) Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
WO2008103971A3 (en) Prostate cancer survival and recurrence
EP3135774A3 (en) Complex sets of mirnas as non-invasive biomarkers for kidney cancer
WO2009032185A3 (en) Functional assay for indentification of loss-of-function mutations in genes
WO2007120955A3 (en) Genes affecting human memory performance
WO2012101219A3 (en) Complex mirna sets as novel biomarkers for lung diseases
WO2010047561A3 (en) Diagnostic kit for predicting the prognosis of invasive or non-muscle invasive bladder cancer, method for predicting the prognosis of bladder cancer, and bladder cancer medicine screening method
WO2008137089A3 (en) Gene signature of early hypoxia to predict patient survival
WO2007058968A3 (en) Gene expression profiles and methods of use
MX2011006773A (en) Biomarker.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09822237

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09822237

Country of ref document: EP

Kind code of ref document: A2